Real-world experiences of adult individuals or caregivers of children who received teplizumab treatment in stage 2 type 1 diabetes
Aims: This study surveyed individuals and caregivers of children who received teplizumab at stage 2 type 1 diabetes (T1D) to garner real-world experiences and their health outlook for the future following treatment with the first approved disease-modifying immune therapy for delaying the onset of Stage 3 T1D. Materials and Methods: This was a cross-sectional, observational, online survey (conducte
